You are here

Stroke DOI:10.1161/STROKEAHA.113.001304

Apolipoprotein E, statins, and risk of intracerebral hemorrhage.

Publication TypeJournal Article
Year of Publication2013
AuthorsWoo, D, Deka, R, Falcone, GJ, Flaherty, ML, Haverbusch, M, Martini, SR, Greenberg, SM, Ayres, AM, Sauerbeck, L, Kissela, BM, Kleindorfer, DO, Moomaw, CJ, Anderson, CD, Broderick, JP, Rosand, J, Langefeld, CD, Woo, JG
JournalStroke
Volume44
Issue11
Pages3013-7
Date Published2013 Nov
ISSN1524-4628
KeywordsAged, Apolipoproteins E, Case-Control Studies, Cerebral Hemorrhage, Female, Genotype, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Prospective Studies, Risk Factors
Abstract

BACKGROUND AND PURPOSE: Apolipoprotein E (ApoE) genotypes have been associated with lobar intracerebral hemorrhage (ICH). Although statins have been associated with an increased risk of ICH, meta-analyses have not consistently shown a statin-induced risk of ICH. Here, we test whether hypercholesterolemia (HC) and ApoE polymorphisms affect the risk of ICH by statin use.

METHODS: The Genetic and Environmental Risk Factors for Hemorrhagic Stroke (GERFHS) study is a prospective, demographically matched case-control study of ICH. A similar study of ICH, Genetic Risks for Medication-Related Hemorrhagic Stroke (GOCHA), was used as a replication cohort. Subjects were classified as normocholesterolemia, HC without statin use, and HC with statin use. Statistical comparisons were performed using Fisher exact test, χ2 tests, and the Breslow-Day test.

RESULTS: The discovery cohort consisted of 558 ICH cases and 1444 controls, and the replication cohort consisted of 1020 ICH cases and 382 controls. The association of lower risk for HC was not attenuated by statin use. Statin use was observed to confer a higher risk for lobar ICH in those carrying ApoE4/E4 and ApoE2/E4 genotypes in both discovery and replication cohorts, and a test for interaction showed a trend towards significance (P=0.11 for statin and ApoE4/E4).

CONCLUSIONS: Statin use does not seem to attenuate the association of HC with decreased risk for nonlobar ICH. Our data support a gene-by-drug effect for lobar ICH, but larger sample sizes are needed to confirm the association before any clinical change is warranted.

CLINICAL TRIAL REGISTRATION URL: http://clinicaltrials.gov. Unique identifier: NCT00930280.

URLhttp://stroke.ahajournals.org/cgi/pmidlookup?view=long&pmid=24008570
DOI10.1161/STROKEAHA.113.001304
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/24008570?dopt=Abstract

Alternate JournalStroke
PubMed ID24008570
PubMed Central IDPMC3873717
Grant ListR-01-NS 36695 / NS / NINDS NIH HHS / United States
U10 NS077311 / NS / NINDS NIH HHS / United States
P30 ES006096 / ES / NIEHS NIH HHS / United States
R-01-ES 06096 / ES / NIEHS NIH HHS / United States
R01 NS059727 / NS / NINDS NIH HHS / United States
R01NS059727 / NS / NINDS NIH HHS / United States
R01 NS036695 / NS / NINDS NIH HHS / United States
M01 RR000042 / RR / NCRR NIH HHS / United States
UL1 TR000077 / TR / NCATS NIH HHS / United States